Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - labetalol hydrochloride, quantity: 200 mg - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; methyl hydroxybenzoate; lactose monohydrate; hypromellose; propyl hydroxybenzoate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; sodium benzoate; industrial methylated spirit - indications as at 24 oct 1996 : treatment of all grades of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - labetalol hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: methyl hydroxybenzoate; lactose monohydrate; maize starch; propyl hydroxybenzoate; hypromellose; magnesium stearate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; sodium benzoate; industrial methylated spirit - indications as at 24 oct 1996 : treatment of all grades of hypertension.

United States - English - NLM (National Library of Medicine)

prometheus laboratories inc. - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - trandate tablets are indicated in the management of hypertension. trandate tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. trandate tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - labetalol hydrochloride -

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - tablets - labetalol hydrochloride 200 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - tablets - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Ireland - English - HPRA (Health Products Regulatory Authority)

rph pharmaceuticals ab - labetalol hydrochloride - solution for injection - 5 milligram(s)/millilitre - alpha and beta blocking agents; labetalol

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - injection - see ingredients - each 1 ml solution contains labetalol hydrochloride 5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - labetalol hydrochloride 5 mg/ml;  ;  ;   - solution for injection - 5 mg/ml - active: labetalol hydrochloride 5 mg/ml       excipient: hydrochloric acid sodium hydroxide water for injection - -hypertensive episodes following acute myocardial infarction. -severe hypertension when rapid control of blood pressure is essential.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rph pharmaceuticals ab - labetalol hydrochloride - oral tablet - 100mg